Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) exon 20 in-frame insertions occur in ~4% of EGFR-mutated non-small cell lung cancer (NSCLC).
• Human epidermal growth factor receptor 2 gene (HER2) mutations, primarily exon 20 insertions (~90%), are found in 2-4% of NSCLC patients.
• These mutations confer resistance to existing EGFR tyrosine kinase inhibitors (TKIs) and anti-HER2 therapies due to steric hindrance of the drug-binding pocket.

Purpose of the Study:

• To review current data on EGFR and HER2 exon 20 driver mutations in NSCLC.
• To summarize the unmet clinical need for targeted therapies against these mutations.
• To discuss emerging novel targeted therapies showing promising activity.

Main Methods:

• Literature review of studies reporting on EGFR/HER2 exon 20 mutations in NSCLC.
• Analysis of data on the efficacy of novel targeted agents.
• Synthesis of information on molecular alterations and treatment strategies.

Main Results:

• EGFR and HER2 exon 20 mutations represent a distinct subset of NSCLC with intrinsic resistance to standard TKIs.
• No targeted therapies are currently approved for these specific mutations, highlighting a significant unmet need.
• Early clinical data indicate encouraging activity of novel drugs specifically designed to target these EGFR and HER2 mutations.

Conclusions:

• EGFR and HER2 exon 20 mutations in NSCLC are challenging targets due to drug resistance.
• Development of novel targeted therapies is crucial for improving outcomes in patients with these mutations.
• Emerging targeted treatments offer new hope and potential therapeutic options for metastatic NSCLC patients with these driver alterations.